Read about the latest insights in skin cancer care with a new whitepaper on advanced basal cell carcinoma and advanced cutaneous squamous cell carcinoma. View the complimentary resource today!
In this video, Dr Atanaskova-Mesinkovska shares what she’ll be covering during her session, “What You Need To Know NOW About Alopecia Areata,” to be presented at the 2023 Fall Clinical Dermatology Conference.
In this video, Dr Atanaskova-Mesinkovska shares what she’ll be covering during her session, “What You Need To Know NOW About Alopecia Areata,” to be presented at the 2023 Fall Clinical Dermatology Conference.
A recent study examines the adverse reactions to dermal fillers in the oral and maxillofacial regions, enhancing the understanding of complications associated with cosmetic procedures.
A recent study examines the adverse reactions to dermal fillers in the oral and maxillofacial regions, enhancing the understanding of complications associated with cosmetic procedures.
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
Researchers investigated changes in biomarker levels among responders and nonresponders to tumor necrosis factor alpha inhibitor (TNFi) and IL-17A inhibitor (IL-17Ai) treatments in patients with psoriatic arthritis.
Researchers investigated changes in biomarker levels among responders and nonresponders to tumor necrosis factor alpha inhibitor (TNFi) and IL-17A inhibitor (IL-17Ai) treatments in patients with psoriatic arthritis.
Which of the following clinical features is most strongly associated with an increased risk of developing psoriatic arthritis in patients with psoriasis?
Which of the following clinical features is most strongly associated with an increased risk of developing psoriatic arthritis in patients with psoriasis?
Clinicians vary in when they escalate to JAK inhibitor therapy for alopecia areata. Take the quiz to see if your threshold aligns with current expert consensus.
Clinicians vary in when they escalate to JAK inhibitor therapy for alopecia areata. Take the quiz to see if your threshold aligns with current expert consensus.
Older patients need special consideration. Take the quiz to identify which systemic drug class carries higher risks—like thrombosis and malignancy—and requires extra caution in aging populations.
Older patients need special consideration. Take the quiz to identify which systemic drug class carries higher risks—like thrombosis and malignancy—and requires extra caution in aging populations.
Explore the ethical flaws in labeling alopecia areata as a cosmetic concern. Take the quiz to uncover the strongest rationale for reclassifying AA as a medical condition.
Explore the ethical flaws in labeling alopecia areata as a cosmetic concern. Take the quiz to uncover the strongest rationale for reclassifying AA as a medical condition.